University of Iowa Hospitals and Clinics, Department of Obstetrics and Gynecology, 200 Hawkins Drive, Iowa City, IA, 52242.
University of Iowa Hospitals and Clinics, Department of Obstetrics and Gynecology, 200 Hawkins Drive, Iowa City, IA, 52242.
Contraception. 2019 Aug;100(2):160-164. doi: 10.1016/j.contraception.2019.04.006. Epub 2019 Apr 17.
Data on the practice of self-managed medication abortion are limited, in part because this practice takes place purposefully outside of established healthcare systems. Given this, we aimed to ascertain abortion providers' familiarity with self-managed medication abortion and associated complications, compare regional differences and evaluate provider attitudes.
We distributed an online survey to members of Society for Family Planning, Association of Reproductive Health Providers and the Abortion Care Network between July and September 2017 querying experiences with and opinions about self-managed abortion.
Of 650 respondents, 359 (55.1%) were direct abortion providers. Two hundred and thirty of 335 providers (68.6%) had experience with women trying to interrupt pregnancies on their own, and of those, 153 (76.1%) had seen use of misoprostol and/or mifepristone, and 204 of 342 (59.6%) thought this practice increased in the past 5 years. One hundred and seventeen of 335 (34.9%), witnessed complications from self-managed abortion with misoprostol/mifepristone, most commonly incomplete abortion and less often hemorrhage, sepsis and uterine rupture. Half of providers, 171 of 321 (53.3%), think that the use of misoprostol/mifepristone for the self-management of abortion is safe.
Two thirds of respondents had experiences with women attempting to self-manage abortion, and about a third witnessed complications related to self-managed medication abortion. About half of respondents agreed that self-managed abortion is safe.
This study establishes that self-managed abortion is a practice which a majority of respondents have seen among their patients and, because of its prevalence, an area that warrants further research.
关于自行管理药物流产实践的数据有限,部分原因是这种实践是在既定医疗体系之外有目的地进行的。鉴于此,我们旨在确定堕胎提供者对自行管理药物流产及其相关并发症的熟悉程度,比较区域差异,并评估提供者的态度。
我们于 2017 年 7 月至 9 月期间向计划生育协会、生殖健康提供者协会和堕胎护理网络的成员分发了一份在线调查,询问他们对自行堕胎的经验和看法。
在 650 名受访者中,有 359 名(55.1%)是直接堕胎提供者。在 335 名提供者中有 230 名(68.6%)有过女性试图自行终止妊娠的经验,其中 153 名(76.1%)见过米非司酮和/或米索前列醇的使用,204 名(59.6%)认为这种做法在过去 5 年有所增加。在 335 名提供者中有 117 名(34.9%)目睹了自行管理药物流产的并发症,最常见的是不完全流产,较少见的是出血、败血症和子宫破裂。一半的提供者,即 171 名(53.3%)认为使用米非司酮/米索前列醇自行管理堕胎是安全的。
三分之二的受访者有过女性试图自行管理堕胎的经验,约三分之一的受访者目睹了与自行管理药物流产相关的并发症。约一半的受访者认为自行管理堕胎是安全的。
这项研究表明,自行管理药物流产是大多数受访者在患者中看到的一种做法,而且由于其普遍存在,这是一个需要进一步研究的领域。